Skip to main content

Table 1 Deriving the PNH risk-factor score

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Clinical indicator

Specific level of clinical indicator

Assigned value

Observed LDH category

LDH < 1.5×ULN

2

 

LDH 1.5–< 3×ULN

4

 

LDH ≥ 3xULN

6

Observed pRBC stratum

0 unit pRBC

NA

 

1–14 units pRBC

NA

 

> 14 units pRBC

NA

Immuno-suppressant treatment

No

1

 

Yes

2

Aplastic anemia

No

1

 

Yes

2

Myelodysplastic syndrome

No

1

 

Yes

2

Bone marrow disorder

No

1

 

Yes

2

Summary score creation

  

Sum all assigned values

Sum assigned values for observed LDH, Immuno-suppressant treatment, aplastic anemia, myelodysplastic syndrome, and bone marrow disorder

 

Create PNH risk-factor group

  
 

Lower

6–8

 

Higher

9–12

  1. NA: Since pRBC was not used in the 302 trial, it was not included among the clinical indicators used for the risk-factor score